Abstract
Purpose :
Because of a medical and economic burden of repeated intravitreal anti-vascular endothelial growth factor injection for the exudative age-related macular degeneration (AMD), research that can reduce the injection freuqency has been done. We performed a retrospective, observational study to evaluate the efficacy of topical bromfenac 0.09% combined with intravitreal aflibercept (IVA) injection in the treatment of exudative AMD during two years.
Methods :
Forty three patients (43 eyes) with exudative AMD who received IVA injections as-needed protocol for 2 years were enrolled. Among the 43 eyes, 25 received only IVA (IVA group), whereas 18 received a combination of IVA and topical bromfenac 0.09% (bromfenac group). We compared the total number of IVA injections and changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) between two groups.
Results :
The bromfenac group received a significantly lower number of IVA injections compared with the IVA group during 2 years (7.4 ± 1.0, vs. 9.0 ± 1.9, p < 0.01). BCVA and CRT at 2 year improved compared to their baseline values in both groups (p < 0.05, respectively). Changes in BCVA and CRT at 2 year did not differ between two groups (p = 0.786 and p = 0.905, respectively). None of the groups showed complications including endophthalmitis or corneoscleral diseases.
Conclusions :
Combined topical bromfenac treatment can be useful to reduce the injection frequency of IVA for patients with exudative AMD.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.